Tempus AI Stock Price, News & Analysis

Tempus (NASDAQ: TEM) has received FDA 510(k) clearance for its updated Tempus Pixel cardiac imaging platform. The enhanced AI-powered device now generates T1 and T2 inline maps for cardiac MR image analysis, enabling precise numerical values for tissue characteristics and detection of conditions like fibrosis, inflammation, and edema.

The platform provides advanced viewing and automated reporting capabilities, improving efficiency in flow visualization, functional analysis, and tissue characterization. Notably, Tempus Pixel can generate these maps directly from raw MRI data, even when the scanner cannot produce them natively.

This development follows Tempus's strategic acquisitions, including Arterys in 2022 and Paige, which added AI-powered imaging tools and a dataset of nearly 7 million clinically annotated pathology slides to Tempus's precision medicine platform.

Tempus (NASDAQ: TEM) has published a significant study in JCO Precision Oncology validating their PurIST® algorithm for pancreatic cancer treatment selection. The study, analyzing 931 patients with advanced pancreatic ductal adenocarcinoma (PDAC), demonstrates PurIST's effectiveness in guiding first-line chemotherapy choices.

The algorithm classifies PDAC tumors into "classical" or "basal" subtypes, showing that classical subtype patients treated with FOLFIRINOX achieved a median overall survival of 11.8 months versus 7.0 months for basal subtype patients. Notably, classical subtype patients with good performance status showed a 33% reduced risk of death when treated with FOLFIRINOX compared to alternative therapy.

Tempus (NASDAQ: TEM) and Northwestern Medicine announced a significant expansion of their partnership, making Northwestern Medicine the first health system to integrate David, Tempus' generative AI clinical co-pilot, into its electronic health record (EHR) platform.

The integration will enable Northwestern Medicine's clinical teams to build custom AI agents, query patient data using natural language, automate pre-appointment preparation, receive real-time support during appointments, and streamline post-appointment tasks. This collaboration builds on their decade-long partnership in data-driven healthcare.

The implementation aims to enhance care delivery by providing physicians with real-time, AI-enabled insights and reducing administrative burden while improving patient outcomes.

Tempus AI (NASDAQ: TEM), an AI-driven precision medicine technology company, announced its participation in Morgan Stanley's 23rd Annual Global Healthcare Conference in New York City from September 8-10, 2025. Founder and CEO Eric Lefkofsky and CFO Jim Rogers will engage in a fireside chat on September 8 from 1:05 to 1:40 p.m. EST. The discussion will be accessible via live audio webcast.

Tempus (NASDAQ: TEM) has announced the acquisition of Paige, an AI-focused digital pathology company, for $81.25 million, primarily paid in Tempus common stock. The acquisition includes Paige's dataset of nearly 7 million digitized pathology slides from 45 countries and the assumption of Paige's Microsoft Azure cloud services agreement.

Paige brings significant AI capabilities, including the first FDA-cleared AI application in pathology for cancer detection, and has developed the first million-slide foundation model for cancer. The merger aims to accelerate Tempus's development of the largest oncology foundation model, leveraging Paige's relationship with Memorial Sloan Kettering Cancer Center and their experienced technical team.

Tempus (NASDAQ: TEM) reported strong Q2 2025 financial results with revenue surging 89.6% year-over-year to $314.6 million. The company's genomics revenue grew 115.3% to $241.8 million, driven by significant volume growth in Oncology (26%) and Hereditary (32%) testing. Data and services revenue increased 35.7% to $72.8 million.

The company raised its full-year 2025 guidance to $1.26 billion in revenue and expects positive adjusted EBITDA of $5 million, marking a $110 million improvement over 2024. Tempus also completed a $750 million convertible senior notes offering at 0.75% interest rate, strengthening its financial position. The company's database now contains over 350 petabytes of clinical and molecular data, with connections to more than 40 million patient records.

Tempus AI (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, has scheduled its Q2 2025 earnings release and conference call for August 8, 2025. The earnings conference call will begin at 8:00 a.m. ET, featuring presentations from CEO Eric Lefkofsky and CFO Jim Rogers.

Investors can access the call through multiple channels, including a live audio webcast on Tempus' Investor Relations website, or by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with Conference ID 7005219.

Tempus (NASDAQ: TEM) has received FDA 510(k) clearance for its Tempus ECG-Low EF software, an AI-powered tool designed to identify patients with low left ventricular ejection fraction (LVEF). This marks the company's second FDA-cleared ECG-AI device in its cardiovascular diagnostic portfolio.

The software analyzes 12-lead ECG recordings to detect signs of LVEF ≤40% in patients aged 40 and older who are at risk of heart failure. The technology is specifically designed for use in healthcare facilities and requires interpretation alongside other diagnostic information and clinical history.

Personalis (Nasdaq: PSNL) has expanded and extended its strategic collaboration with Tempus AI through 2029, adding colorectal cancer (CRC) as the fourth indication for their NeXT Personal® minimal residual disease (MRD) test. The test will now cover breast, lung, and colorectal cancers, plus solid tumor immunotherapy monitoring.

The expansion follows promising interim results from the VICTORI study presented at AACR 2025, showing strong performance in detecting early CRC recurrence. The collaboration leverages Tempus' extensive network reaching over 50% of U.S. oncologists to accelerate the adoption of Personalis' ultra-sensitive cancer recurrence detection technology.